[HTML][HTML] Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome
LA Greenbaum, M Fila, G Ardissino, SI Al-Akash… - Kidney international, 2016 - Elsevier
Atypical hemolytic uremic syndrome (aHUS) is caused by alternative complement pathway
dysregulation, leading to systemic thrombotic microangiopathy (TMA) and severe end-organ …
dysregulation, leading to systemic thrombotic microangiopathy (TMA) and severe end-organ …
Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome
LA Greenbaum, M Fila, G Ardissino… - Kidney …, 2016 - pubmed.ncbi.nlm.nih.gov
Atypical hemolytic uremic syndrome (aHUS) is caused by alternative complement pathway
dysregulation, leading to systemic thrombotic microangiopathy (TMA) and severe end-organ …
dysregulation, leading to systemic thrombotic microangiopathy (TMA) and severe end-organ …
[PDF][PDF] Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome
LA Greenbaum, M Fila, G Ardissino… - Kidney …, 2016 - scholar.archive.org
Atypical hemolytic uremic syndrome (aHUS) is caused by alternative complement pathway
dysregulation, leading to systemic thrombotic microangiopathy (TMA) and severe end-organ …
dysregulation, leading to systemic thrombotic microangiopathy (TMA) and severe end-organ …
[引用][C] Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome
LA Greenbaum, M Fila, G Ardissino, SI Al-Akash… - Kidney …, 2016 - cir.nii.ac.jp
Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic
uremic syndrome | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細 …
uremic syndrome | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細 …
Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome
LA Greenbaum, M Fila, G Ardissino… - Kidney …, 2016 - kidney-international.org
Atypical hemolytic uremic syndrome (aHUS) is caused by alternative complement pathway
dysregulation, leading to systemic thrombotic microangiopathy (TMA) and severe end-organ …
dysregulation, leading to systemic thrombotic microangiopathy (TMA) and severe end-organ …
Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
LA Greenbaum, M Fila, G Ardissino, SI Al-Akash… - Kidney …, 2016 - europepmc.org
Atypical hemolytic uremic syndrome (aHUS) is caused by alternative complement pathway
dysregulation, leading to systemic thrombotic microangiopathy (TMA) and severe end-organ …
dysregulation, leading to systemic thrombotic microangiopathy (TMA) and severe end-organ …
Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome
LA Greenbaum, M Fila, G Ardissino… - KIDNEY …, 2016 - biblio.ugent.be
Atypical hemolytic uremic syndrome (aHUS) is caused by alternative complement pathway
dysregulation, leading to systemic thrombotic microangiopathy (TMA) and severe end-organ …
dysregulation, leading to systemic thrombotic microangiopathy (TMA) and severe end-organ …
[PDF][PDF] Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome
LA Greenbaum, M Fila, G Ardissino… - Kidney …, 2016 - cyberleninka.org
Atypical hemolytic uremic syndrome (aHUS) is caused by alternative complement pathway
dysregulation, leading to systemic thrombotic microangiopathy (TMA) and severe end-organ …
dysregulation, leading to systemic thrombotic microangiopathy (TMA) and severe end-organ …
[PDF][PDF] Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome
LA Greenbaum, M Fila, G Ardissino, SI Al-Akash… - 2016 - repository.ubn.ru.nl
Atypical hemolytic uremic syndrome (aHUS) is caused by alternative complement pathway
dysregulation, leading to systemic thrombotic microangiopathy (TMA) and severe end-organ …
dysregulation, leading to systemic thrombotic microangiopathy (TMA) and severe end-organ …
[PDF][PDF] Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome
LA Greenbaum, M Fila, G Ardissino, SI Al-Akash… - Kidney …, 2016 - core.ac.uk
Atypical hemolytic uremic syndrome (aHUS) is caused by alternative complement pathway
dysregulation, leading to systemic thrombotic microangiopathy (TMA) and severe end-organ …
dysregulation, leading to systemic thrombotic microangiopathy (TMA) and severe end-organ …